Sugi Predict

Sugi Predict / Compounds / SCHEMBL933352

SCHEMBL933352

SCHEMBL933352

O=C(Cl)C(Cc1ccccc1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.67
▸ CHRM1 P11229 9/20 0.53
▸ UBE2N P61088 1/20 0.53
▸ CYP1A2 P05177 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ NCOA1 Q15788 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ NCOA3 Q9Y6Q9 1/20 0.49
▸ ACP3 P15309 1/20 0.47
▸ ALPI P09923 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ XIAP P98170 1/20 0.47
▸ SLC7A5 Q01650 1/20 0.47
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22394830 0.89 EPHX1 (0.54) EPHX1CHRM1UBE2NCYP1A2
SCHEMBL11149194 0.86 EPHX1 (0.51) EPHX1CHRM1UBE2NCYP1A2PTGS1
SCHEMBL6588762 0.84 LDHA (0.57) EPHX1ALDH1A1SMN1; SMN2
SCHEMBL67234 0.83 EPHX1 (0.71) EPHX1CHRM1UBE2NCYP1A2ACP3
SCHEMBL599399 0.83 EPHX1 (0.71) EPHX1CHRM1UBE2NCYP1A2ACP3
SCHEMBL3079795 0.83 EPHX1 (0.71) EPHX1CHRM1UBE2NCYP1A2ACP3
SCHEMBL27600068 0.83 EPHX1 (0.71) EPHX1CHRM1UBE2NCYP1A2ACP3
SCHEMBL2204134 0.83 EPHX1 (0.47) EPHX1CHRM1UBE2NCYP1A2ALDH1A1
SCHEMBL1234701 0.82 EPHX1 (0.69) EPHX1CHRM1UBE2NCYP1A2ACP3
Hydrochloric Acid SCHEMBL933353 0.82 EPHX1 (0.69) EPHX1CHRM1UBE2NCYP1A2ALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704117-B1 AZABICYCLO DERIVATIVES FOR TREATING OCULAR DISORDERS ALCON INC (CH) 2026-01-28 — — EP disclosed
US-12247028-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2025-03-11 — — US disclosed
US-20240132497-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2024-04-25 — — US disclosed
US-11884666-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2024-01-30 — — US disclosed
US-20220267328-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2022-08-25 — — US disclosed
US-11306090-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2022-04-19 — — US disclosed
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2021-06-17 — — US disclosed
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2021-06-17 — — US disclosed
EP-3704117-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES FOR TREATING OCULAR DISORDERS ALCON INC. (CH) 2020-09-09 — — EP disclosed
CN-111247147-A Azabicyclo and diazepatriene derivatives useful for treating ocular disorders 爱尔康公司 2020-06-05 — — CN disclosed
EP-1183239-A1 AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2002-03-06 — — EP disclosed
US-6294668-B1 ANTIBACTERIAL ACTIVITY AGAINST BETA-LACTAM SENSITIVE AND RESISTANT GRAM-POSITIVE BACTERIA, SUCH AS STAPHYLOCOCCI, PNEUMOCOCCI, AND ENTEROCOCCI; USED IN THERAPY OF INFECTIOUS DISEASES CAUSED BY THOSE BACTERIA HOFFMAN-LA ROCHE INC. 2001-09-25 — — US disclosed
WO-2000069821-A1 AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-11-23 — — WO disclosed
EP-0984778-A4 NEUROPEPTIDE-Y LIGANDS ALANEX CORP (US) 2000-06-07 — — EP disclosed
EP-0984778-A1 NEUROPEPTIDE-Y LIGANDS Alanex Corporation (US) 2000-03-15 — — EP disclosed
EP-0841339-A1 Vinylpyrrolidinon cephalosporin derivatives F. HOFFMANN-LA ROCHE AG (CH) 1998-05-13 — — EP disclosed
WO-1998007420-A1 NEUROPEPTIDE-Y LIGANDS AGOURON ACQUISITION CORP. (US) 1998-02-26 — — WO disclosed
US-5236956-A Compounds for the treatment of urinary incontinence KABI PHARMACIA AKTIEBOLAG (SE) 1993-08-17 — — US disclosed
EP-0367040-B1 COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE Kabi Pharmacia AB (SE) 1993-04-21 — — EP disclosed
EP-0367040-A1 Compounds for the treatment of urinary incontinence Kabi Pharmacia AB (SE) 1990-05-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884666-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 EPHX1 1173/4885CHRM1 9/4885UBE2N 3830/4885
US-20240132497-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 EPHX1 1173/4885CHRM1 9/4885UBE2N 3830/4885
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 EPHX1 1173/4885CHRM1 9/4885UBE2N 3830/4885
US-20220267328-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 EPHX1 1173/4885CHRM1 9/4885UBE2N 3830/4885
US-12247028-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 EPHX1 1173/4885CHRM1 9/4885UBE2N 3830/4885
US-11306090-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 EPHX1 1173/4885CHRM1 9/4885UBE2N 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.